Regulating Tumorigenicity and Cancer Metastasis through TRKA Signaling
Curr Cancer Drug Targets. 2023 Sep 4. doi: 10.2174/1568009623666230904150957. Online ahead of print.ABSTRACTTropomyosin receptor kinase (TRK) A, TRKA, is a specific binding receptor of nerve growth factor (NGF), which plays an essential role in the occurrence and progression of human cancers. TRKA overexpression has been proven to be a powerful carcinogenic driver and has been verified in many tumors. The TRKA receptor kinase domain is over-activated in an NGF-dependent manner, accompanied by activation of downstream signal pathways, such as RAS-MAPK, PI3K-AKT, JAK2-STAT3 pathway, PLC γ pathway, and Hippo pathway, which p...
Source: Current Cancer Drug Targets - September 6, 2023 Category: Cancer & Oncology Authors: Yichao Fan Boya Zhang Xinhui Du Bangmin Wang Qiang Yan Liangyu Guo Weitao Yao Source Type: research
Regulating Tumorigenicity and Cancer Metastasis through TRKA Signaling
Curr Cancer Drug Targets. 2023 Sep 4. doi: 10.2174/1568009623666230904150957. Online ahead of print.ABSTRACTTropomyosin receptor kinase (TRK) A, TRKA, is a specific binding receptor of nerve growth factor (NGF), which plays an essential role in the occurrence and progression of human cancers. TRKA overexpression has been proven to be a powerful carcinogenic driver and has been verified in many tumors. The TRKA receptor kinase domain is over-activated in an NGF-dependent manner, accompanied by activation of downstream signal pathways, such as RAS-MAPK, PI3K-AKT, JAK2-STAT3 pathway, PLC γ pathway, and Hippo pathway, which p...
Source: Current Cancer Drug Targets - September 6, 2023 Category: Cancer & Oncology Authors: Yichao Fan Boya Zhang Xinhui Du Bangmin Wang Qiang Yan Liangyu Guo Weitao Yao Source Type: research
Regulating Tumorigenicity and Cancer Metastasis through TRKA Signaling
Curr Cancer Drug Targets. 2023 Sep 4. doi: 10.2174/1568009623666230904150957. Online ahead of print.ABSTRACTTropomyosin receptor kinase (TRK) A, TRKA, is a specific binding receptor of nerve growth factor (NGF), which plays an essential role in the occurrence and progression of human cancers. TRKA overexpression has been proven to be a powerful carcinogenic driver and has been verified in many tumors. The TRKA receptor kinase domain is over-activated in an NGF-dependent manner, accompanied by activation of downstream signal pathways, such as RAS-MAPK, PI3K-AKT, JAK2-STAT3 pathway, PLC γ pathway, and Hippo pathway, which p...
Source: Current Cancer Drug Targets - September 6, 2023 Category: Cancer & Oncology Authors: Yichao Fan Boya Zhang Xinhui Du Bangmin Wang Qiang Yan Liangyu Guo Weitao Yao Source Type: research
Regulating Tumorigenicity and Cancer Metastasis through TRKA Signaling
Curr Cancer Drug Targets. 2023 Sep 4. doi: 10.2174/1568009623666230904150957. Online ahead of print.ABSTRACTTropomyosin receptor kinase (TRK) A, TRKA, is a specific binding receptor of nerve growth factor (NGF), which plays an essential role in the occurrence and progression of human cancers. TRKA overexpression has been proven to be a powerful carcinogenic driver and has been verified in many tumors. The TRKA receptor kinase domain is over-activated in an NGF-dependent manner, accompanied by activation of downstream signal pathways, such as RAS-MAPK, PI3K-AKT, JAK2-STAT3 pathway, PLC γ pathway, and Hippo pathway, which p...
Source: Current Cancer Drug Targets - September 6, 2023 Category: Cancer & Oncology Authors: Yichao Fan Boya Zhang Xinhui Du Bangmin Wang Qiang Yan Liangyu Guo Weitao Yao Source Type: research
Regulating Tumorigenicity and Cancer Metastasis through TRKA Signaling
Curr Cancer Drug Targets. 2023 Sep 4. doi: 10.2174/1568009623666230904150957. Online ahead of print.ABSTRACTTropomyosin receptor kinase (TRK) A, TRKA, is a specific binding receptor of nerve growth factor (NGF), which plays an essential role in the occurrence and progression of human cancers. TRKA overexpression has been proven to be a powerful carcinogenic driver and has been verified in many tumors. The TRKA receptor kinase domain is over-activated in an NGF-dependent manner, accompanied by activation of downstream signal pathways, such as RAS-MAPK, PI3K-AKT, JAK2-STAT3 pathway, PLC γ pathway, and Hippo pathway, which p...
Source: Current Cancer Drug Targets - September 6, 2023 Category: Cancer & Oncology Authors: Yichao Fan Boya Zhang Xinhui Du Bangmin Wang Qiang Yan Liangyu Guo Weitao Yao Source Type: research
Ligand-mediated Targeted Drug Delivery Approaches against Hepatocellular Carcinoma
Curr Cancer Drug Targets. 2023;23(11):879-888. doi: 10.2174/1568009623666230503094346.ABSTRACTOne of the most important health problems in the world today is cancer. The World Health Organization (WHO) reported that it results in 8.9 million deaths annually. Malignant tumours and unregulated cell proliferation are features of malignant neoplasms, which can also invade nearby body regions. Hepatocellular carcinoma is the third most prevalent cause of cancer-related death worldwide and the fifth most common kind of cancer, according to a recent analysis. Patients with liver disease as well as chronic hepatitis B and C are mo...
Source: Current Cancer Drug Targets - September 1, 2023 Category: Cancer & Oncology Authors: Amrita Singh Sudhanshu Mishra Saurabh Sharma Smriti Ojha Sunil Yagnik Sudhi Pandey Source Type: research
Ligand-mediated Targeted Drug Delivery Approaches against Hepatocellular Carcinoma
Curr Cancer Drug Targets. 2023;23(11):879-888. doi: 10.2174/1568009623666230503094346.ABSTRACTOne of the most important health problems in the world today is cancer. The World Health Organization (WHO) reported that it results in 8.9 million deaths annually. Malignant tumours and unregulated cell proliferation are features of malignant neoplasms, which can also invade nearby body regions. Hepatocellular carcinoma is the third most prevalent cause of cancer-related death worldwide and the fifth most common kind of cancer, according to a recent analysis. Patients with liver disease as well as chronic hepatitis B and C are mo...
Source: Current Cancer Drug Targets - September 1, 2023 Category: Cancer & Oncology Authors: Amrita Singh Sudhanshu Mishra Saurabh Sharma Smriti Ojha Sunil Yagnik Sudhi Pandey Source Type: research
Ligand-mediated Targeted Drug Delivery Approaches against Hepatocellular Carcinoma
Curr Cancer Drug Targets. 2023;23(11):879-888. doi: 10.2174/1568009623666230503094346.ABSTRACTOne of the most important health problems in the world today is cancer. The World Health Organization (WHO) reported that it results in 8.9 million deaths annually. Malignant tumours and unregulated cell proliferation are features of malignant neoplasms, which can also invade nearby body regions. Hepatocellular carcinoma is the third most prevalent cause of cancer-related death worldwide and the fifth most common kind of cancer, according to a recent analysis. Patients with liver disease as well as chronic hepatitis B and C are mo...
Source: Current Cancer Drug Targets - September 1, 2023 Category: Cancer & Oncology Authors: Amrita Singh Sudhanshu Mishra Saurabh Sharma Smriti Ojha Sunil Yagnik Sudhi Pandey Source Type: research
Ligand-mediated Targeted Drug Delivery Approaches against Hepatocellular Carcinoma
Curr Cancer Drug Targets. 2023;23(11):879-888. doi: 10.2174/1568009623666230503094346.ABSTRACTOne of the most important health problems in the world today is cancer. The World Health Organization (WHO) reported that it results in 8.9 million deaths annually. Malignant tumours and unregulated cell proliferation are features of malignant neoplasms, which can also invade nearby body regions. Hepatocellular carcinoma is the third most prevalent cause of cancer-related death worldwide and the fifth most common kind of cancer, according to a recent analysis. Patients with liver disease as well as chronic hepatitis B and C are mo...
Source: Current Cancer Drug Targets - September 1, 2023 Category: Cancer & Oncology Authors: Amrita Singh Sudhanshu Mishra Saurabh Sharma Smriti Ojha Sunil Yagnik Sudhi Pandey Source Type: research
Silencing TRIM29 Sensitizes Non-small Cell Lung Cancer Cells to Anlotinib by Promoting Apoptosis via Binding RAD50
CONCLUSION: Finally, we concluded that the increased sensitivity to anlotinib in NSCLC/AR cells was achieved by knocking down TRIM29, besides, the positive effects of TRIM29 knockdown were attributed to the promotion of apoptosis via binding to RAD50 in NSCLC/AR cell nucleus. Therefore, TRIM29 might become a potential target for overcoming anlotinib resistance in NSCLC treatment.PMID:37644752 | DOI:10.2174/1568009623666230829143148 (Source: Current Cancer Drug Targets)
Source: Current Cancer Drug Targets - August 30, 2023 Category: Cancer & Oncology Authors: Min Wu Meng-Meng Jin Xiao-Hui Cao Lei Zhao Yong-Huai Li Source Type: research
Silencing TRIM29 Sensitizes Non-small Cell Lung Cancer Cells to Anlotinib by Promoting Apoptosis via Binding RAD50
CONCLUSION: Finally, we concluded that the increased sensitivity to anlotinib in NSCLC/AR cells was achieved by knocking down TRIM29, besides, the positive effects of TRIM29 knockdown were attributed to the promotion of apoptosis via binding to RAD50 in NSCLC/AR cell nucleus. Therefore, TRIM29 might become a potential target for overcoming anlotinib resistance in NSCLC treatment.PMID:37644752 | DOI:10.2174/1568009623666230829143148 (Source: Current Cancer Drug Targets)
Source: Current Cancer Drug Targets - August 30, 2023 Category: Cancer & Oncology Authors: Min Wu Meng-Meng Jin Xiao-Hui Cao Lei Zhao Yong-Huai Li Source Type: research
Silencing TRIM29 Sensitizes Non-small Cell Lung Cancer Cells to Anlotinib by Promoting Apoptosis via Binding RAD50
CONCLUSION: Finally, we concluded that the increased sensitivity to anlotinib in NSCLC/AR cells was achieved by knocking down TRIM29, besides, the positive effects of TRIM29 knockdown were attributed to the promotion of apoptosis via binding to RAD50 in NSCLC/AR cell nucleus. Therefore, TRIM29 might become a potential target for overcoming anlotinib resistance in NSCLC treatment.PMID:37644752 | DOI:10.2174/1568009623666230829143148 (Source: Current Cancer Drug Targets)
Source: Current Cancer Drug Targets - August 30, 2023 Category: Cancer & Oncology Authors: Min Wu Meng-Meng Jin Xiao-Hui Cao Lei Zhao Yong-Huai Li Source Type: research
Comprehensive analysis of the role of CXCL family members in clear cell renal cell carcinoma
Conclusion In this study, we evaluated the expression levels of CXCL genes in KIRC and their prognostic potential in KIRC. CXCL-5,-9,-10,-11,-12, and -13 may be associated with ccRCC progression, and CXCL-1,-2,-5,-13, and -14 may be potential prognostic markers.PMID:37641996 | DOI:10.2174/1568009623666230825154419 (Source: Current Cancer Drug Targets)
Source: Current Cancer Drug Targets - August 29, 2023 Category: Cancer & Oncology Authors: Jiechuan Qiu Zicheng Wang Peizhi Zhang Yingkun Xu Tianmin Yang Qinghua Xia Source Type: research
A Comprehensive Review on Current Treatments and Challenges Involved in the Treatment of Ovarian Cancer
In conclusion, tailored nanocarriers would optimize medication delivery into the intracellular compartment before optimizing intra-tumour distribution. Other novel treatment possibilities for ovarian cancer include tumour vaccines, gene therapy, targeting epigenetic alteration, and biologically targeted compounds. These characteristics might enhance the therapeutic efficacy.PMID:37642226 | DOI:10.2174/1568009623666230811093139 (Source: Current Cancer Drug Targets)
Source: Current Cancer Drug Targets - August 29, 2023 Category: Cancer & Oncology Authors: Saika Saman Nimisha Srivastava Mohd Yasir Iti Chauhan Source Type: research
GRP78 is Overexpressed in Non-small Cell Lung Cancer Tissues and is Associated with High VEGF Expression in Squamous Cell Carcinoma: A Pilot Study
CONCLUSION: GRP78 overexpression was revealed in most of the investigated samples. The positive association between VEGF and GRP78 may indicate the proangiogenic role of GRP78 in lung cancer. Moreover, the positive association between VEGF and CD31 expression levels suggests that VEGF may cooperate with CD31 to promote angiogenesis in NSCLC.PMID:37638596 | DOI:10.2174/1568009623666230418111020 (Source: Current Cancer Drug Targets)
Source: Current Cancer Drug Targets - August 28, 2023 Category: Cancer & Oncology Authors: Maha Al-Keilani Mohammad A Alqudah Basima Almomani Moath M Alrjoub Batool A Shhabat Karem Alzoubi Source Type: research
